Strategic Partnerships CNX Therapeutics has a growing global distribution footprint across 60+ countries and recently expanded via a Canada distribution partnership with Innomar Strategies. This indicates strong collaboration opportunities with regional distributors and potential co-marketing or co-licensing deals to accelerate market access.

US Market Entry With announced US commercial partnerships for Ethyol (amifostine) and plans to launch in July 2026, there is an active push into the US market. This creates opportunities to align complementary CNS and critical care product lines with Legacy Pharma or similar partners for accelerated US access.

Executive Growth New leadership appointments, including a Chief Operating Officer and Chief Corporate Development Officer, signal a focus on scale, strategic deals, and corporate development. This opens doors for relationship-led engagements around licensing, co-development, and portfolio expansion discussions.

Portfolio Expansion Acquisition of tacrolimus rights and a diversified portfolio in CNS and critical care present recurring upsell and cross-sell opportunities with hospital systems, specialty pharmacies, and contract research organizations seeking diversified essential medicines in Europe and beyond.

Sustainability Edge As a B Corp certified organization with a patient-centric mission and internship program, CNX can leverage ESG credentials in procurement and public tenders, appealing to sustainability-minded customers and partners seeking responsible supply chain and social impact alignment.